PROGRAMAÇÃO CIENTÍFICA
Sexta-feira - 15/06/18
10:30 às 12:30
Reunião dos grupos cooperativos (LACOG, GBECAM, EVA, GBOT, GTG).
Apenas para convidados
13:00 às 14:00
Simpósio Satélite - Roche
14:00
Abertura
14:10 às 15:10
Módulo I – GINECOLÓGICO
Coordenadora: Aknar Calabrich (BA)
14:10 às 14:17 Abstract: 5500 - Comparison of survival between upfront primary debulking surgery versus
neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
Palestrante: Andréia Cristina de Melo (RJ)
14:18 às 14:25 Abstract: 5505 - Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for
uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. Palestrante: Angélica Nogueira Rodrigues (MG)
14:26 às 14:33 Abstract: 5506 - Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer
patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B- MaNGO OV2B-ENGOT OV17
Palestrante: Daniela de Freitas (SP)
14:34 às 14:41 Abstract: 5508 - Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel,
Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab Palestrante: Maria Del Pilar Estevez Diz (SP)
14:42 às 15:10 Discussão
15:10 às 16:00
Módulo II – MELANOMA
Coordenador: Sérgio Jobin Azevedo (RS)
15:10 às 15:17 Abstract: 108 - Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with
unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study Palestrante: Andréia Cristina de Melo (RJ)
15:18 às 15:25 Abstract: 9501 - Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node
dissection in melanoma patients with positive sentinel node Palestrante: Sérgio Jobin Azevedo (RS)
15:25 às 15:32 Abstract: 9502 - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete
resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Palestrante: Rodrigo Guedes (BA)
15:33 às 15:40 Abstract: 9504 - Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus
Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma Palestrante: Rodrigo R. Munhoz (SP)
15:40 às 16:00 Discussão
16:30 às 18:00
Módulo III – PULMÃO
Coordenador: Artur Katz (SP)
16:30 às 16:40 Abstract: 8507 - Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, ≥
3rd line small cell lung cancer: results from the Phase 2 TRINITY study.
Abstract: 8503 - DREAM: A Phase II study of Durvalumab with first line chemotherapy in Mesothelioma: First Results.
Palestrante: Clarissa Mathias (BA)
16:41 às 16:51 Abstract: 8506 - Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC):
KEYNOTE-158.
Abstract: 9006 - Phase III study comparing bevacizumab plus erlotinib to erlotinibin patients with untreated NSCLC harboring activating EGFRmutations. NEJ026.
Palestrante: Carolina Kawamura Haddad (SP)
16:52 às 16:59 Abstract: LBA9000 - IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study
of Atezolizumab + Carboplatin + Paclitaxel or Nab- Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC.
Palestrante: Luiz Henrique de Lima Araújo (RJ)
17:00 às 17:07 Abstract: 9001 - Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment
for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study.
Palestrante: Mauro Zukin (RJ)
17:08 às 17:15 Abstract: 105 - Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or
placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC). Palestrante: Ana Caroline Zimmer Gelatti (RS)
17:16 às 17:23 Abstract: LBA4 - Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as
first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
Palestrante: Clarissa Baldotto (RJ)
17:24 às 18:00 Discussão
18:00 às 19:00
Simpósio Satélite - Novartis
19:00
Apresentação dos Embaixadores do CURA
PROGRAMAÇÃO CIENTÍFICA
Sábado - 16/06/18
8:00 às 08:50
Simpósio Satélite – LIBBS
8:50 às 10:00
Módulo V – GENITOURINÁRIO
Coordenador: Fernando Maluf (SP)
8:50 às 8:57 Abstract: LBA3 - CARMENA:Cytoreductivenephrectomyfollowedby sunitinib versus sunitinib alone in
nmetastatic renal cell carcinoma—Results of a phase III noninferiority trial Palestrante: Oren Smaletz (SP)
8:58 às 9:05 Abstract: 4500 - Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell
carcinoma (accRCC): results from cohort A of KEYNOTE-427 Palestrante: Fabio A. B. Schutz (SP)
9:06 às 9:13 Abstract: 5000 - A randomized phase III trial between adjuvant docetaxel and surveillance after
radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial Palestrante: André Poisl Fay (RS)
9:14 às 9:21 Abstract: 5001 - 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy:
Preliminary results from a phase 2/3 prospective trial Palestrante: Andrey Soares (SP)
9:22 às 9:29 Abstract: 5003 - Olaparib combined with abiraterone in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC): A randomized Phase II trial Palestrante: Igor Morbeck (DF)
9:30 às 10:00 Discussão
10:00
Coffee Break
10:30
Simpósio Satélite - NOVARTIS
11:30 às 13:00
Módulo VI – MAMA
Coordenador: Sérgio Simon (SP)
Convidado Internacional: Otto Metzger (EUA)
11:30 às 11:37 Abstract: 104 - Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of
durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
Palestrante: José Bines (RJ)
11:38 às 11:45 Abstract: 500 - Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425
postmenopausal patients in the ABCSG-18 trial. Palestrante: Rafael Kaliks (SP)
11:46 às 11:53 Abstract: 506 - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with
HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
Palestrante: Max Mano (SP)
11:54 às 12:01 Abstract: 1000 - Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone
receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
Palestrante: Gustavo Werutsky (RS)
12:02 às 12:09 Abstract: LBA1 - TAILORx: Phase III trial of chemoendocrine therapy versus
endocrinetherapyaloneinhormonereceptor- positive,HER2-negative,nodenegativebreastcancer
andanintermediateprognosis21-generecurrence score Palestrante: Sérgio Simon (SP)
12:10 às 12:17 Abstract:LBA1006 - Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA- mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Palestrante: Tomas Reinert (RS)
12:18 às 12:25 Abstract: 1007 - AZD5363 plus paclitaxel versus placebo plus paclitaxel às first-line therapy for
metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
Palestrante: Daniela Dornelles Rosa (RS)
12:26 às 13:00 Discussão
13:00 às 14:00
Simpósio Satélite - ASTRAZENECA
14:00 às 15:00
Módulo VII – CABEÇA E PESCOÇO
Coordenador: William Nassib William Jr (SP)
14:00 às 14:07 Abstract: 6000 - Resultsofa randomizedphaseIIIstudyof Nimotuzumabin combinationwith concurrent
radiotherapy and Cisplatinversus radiotherapy and Cisplatin alone in locally advanced squamous cell carcinoma of the head and neck
Palestrante: Augusto Mota (BA)
14:08 às 14:15 Abstract: 6006 - Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419
(avisopasem manganese) to reduce duration, incidhoffence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP)
Palestrante: Aline Lauda Freitas Chaves (MG)
14:16 às 14:23 Abstract: 6009 - A phase II randomized trial of nivolumab with stereotactic body radiotherapy
(SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). Palestrante: Pedro de Marchi (SP)
14:24 às 14:31 Abstract: 6008 - Multicenter Phase II Trial of Palbociclib, a Selective
CyclinDependentKinase(CDK)4/6Inhibitor,and CetuximabinPlatinum-ResistantHPVUnrelated(-)
Recurrent/MetastaticHeadandNeckSquamousCell Carcinoma (RM HNSCC). Palestrante: William Nassib William Jr (SP)
14:32 às 15:00 Discussão
15:00
Módulo VIII – GASTROINTESTINAL + COLORRETAL
Coordenador: Paulo Hoff (SP)
Convidado Internacional: Caio Rocha Lima (EUA)
15:00 às 15:07 Abstract: 3501 - Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and
5-fluorouracil (FOLFOX) versus 5-5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer
Palestrante: Rui Weschenfelder (RS)
15:08 às 15:15 Abstract: LBA3503 - A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy
(HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Palestrante: Fabio Ferreira (SP)
15:16 às 15:23 Abstract: 3505 - First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or
single-agent panitumumab às maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
Palestrante: Fernanda Capareli (SP)
15:24 às 15:34 Abstract: 3514 - KEYNOTE-164: Pembrolizumab for Patients With Advanced Microsatellite Instability
High (MSI-H) Colorectal Cancer.
Abstract: 4019 - Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
Palestrante: Jorge Sabbaga (SP)
15:35 às 15:42 Abstract: LBA4001 - Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international
randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas
15:43 às 15:50 Abstract: 4004 - A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)
Palestrante: Rachel Riechelman (SP)
15:51 às 15:58 Abstract: LBA4008 - Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy:
Efficacy and safety in the phase III randomized factorial ASPECT trial. Palestrante: Gabriel Prola (RS)
15:59 às 16:30 Discussão
16:30 às 18:00
Sessão Especial de Encerramento – O que muda na prática
Coordenador: Carlos Barrios (RS)
16: 30 às 16:45 Mama
Palestrante: Otto Metzger (EUA)
16:45 às 17:00 Pulmão
Palestrante: William Nassib William Jr (SP)
17:00 às 17:15 GI
Palestrante: Caio Rocha Lima (EUA)
17:15 às 17:30 GU
Palestrante: Fernando Maluf (SP)
17:30 às 18:00 Outros tumores e Discussão
